$4.45 Million in Sales Expected for Crispr Therapeutics AG (CRSP) This Quarter

Analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to post $4.45 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $11.30 million and the lowest is $500,000.00. Crispr Therapeutics reported sales of $32.33 million in the same quarter last year, which would suggest a negative year over year growth rate of 86.2%. The company is expected to announce its next quarterly earnings results on Thursday, March 14th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $9.10 million for the current year, with estimates ranging from $3.40 million to $23.20 million. For the next financial year, analysts anticipate that the business will post sales of $34.78 million, with estimates ranging from $8.00 million to $91.10 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Thursday, November 8th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $2.64 million. Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 47.32%. The business’s revenue was down 76.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.62) EPS.

Several equities analysts recently weighed in on the stock. BidaskClub upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 3rd. Chardan Capital restated a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a report on Wednesday, August 8th. Zacks Investment Research upgraded shares of Crispr Therapeutics from a “hold” rating to a “strong-buy” rating and set a $42.00 target price on the stock in a report on Tuesday, October 9th. Wells Fargo & Co started coverage on shares of Crispr Therapeutics in a report on Wednesday, October 10th. They issued an “outperform” rating and a $65.00 price objective on the stock. Finally, Raymond James started coverage on shares of Crispr Therapeutics in a report on Thursday, September 20th. They issued an “underperform” rating on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $62.47.

Hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. acquired a new position in Crispr Therapeutics in the 2nd quarter worth $116,000. Signaturefd LLC lifted its holdings in Crispr Therapeutics by 123.8% in the 2nd quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock worth $138,000 after buying an additional 1,300 shares in the last quarter. First Mercantile Trust Co. acquired a new position in Crispr Therapeutics in the 2nd quarter worth $141,000. SeaCrest Wealth Management LLC lifted its holdings in Crispr Therapeutics by 202.9% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 2,726 shares of the company’s stock worth $160,000 after buying an additional 1,826 shares in the last quarter. Finally, TRUE Private Wealth Advisors acquired a new position in Crispr Therapeutics in the 3rd quarter worth $122,000. Hedge funds and other institutional investors own 39.49% of the company’s stock.

NASDAQ:CRSP opened at $36.37 on Friday. Crispr Therapeutics has a twelve month low of $16.70 and a twelve month high of $73.90.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

See Also: What is a conference call?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply